Regeneron Trial Team Talks $406.8M Win in Antitrust Trial Showdown With Cholesterol Drug Rival Amgen 11 minute read May 28, 2025. By. Ross Todd. Email. Share. Print.

Regeneron Pharmaceuticals, Inc. First quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding Ronapreve TM (a)(b), revenues increased 7%. First quarter 2024 ...

Regeneron announced a series of leadership changes Friday, including a transition at the CFO level and updates to the composition of the board of directors. The company announced that CFO Robert E.